Prevail Therapeutics (PRVL) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
August 11, 2020 6:31 AM EDTPreliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinsons Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients
Company Modifies Protocol for PROPEL Trial of PR001 for Parkinsons Disease Patients with GBA1 Mutations; Expects to Continue Enrollment in Second Half of 2020
PROVIDE Trial of PR001 for Type 2 Gaucher Disease and PROCLAIM Trial of PR006 for Frontotemporal Dementia Patients with GRN Mutations Expected to Initiate Enrollment in Second Half of 2020
$75.0 Million At-The-Market Equity Program
... More
